PeptideCompareThymagen — EU research guide.
Thymagen is a synthetic dipeptide (Glu-Trp, also referenced as Oglufanide) from the Khavinson bioregulator series, proposed to modulate immune cell cyclic nucleotide signalling and T-cell regulation. It is the simpler two-amino-acid counterpart to Thymalin, the natural thymic tissue complex PeptideCompare already tracks.
What is Thymagen?
Thymagen is a synthetic dipeptide (Glu-Trp, also referenced as Oglufanide) from the Khavinson bioregulator series, proposed to modulate immune cell cyclic nucleotide signalling and T-cell regulation. It is the simpler two-amino-acid counterpart to Thymalin, the natural thymic tissue complex PeptideCompare already tracks.
What does the research show?
Published research describes immune-modulatory effects mainly in rat studies from the originating research group; clinical trials of the same dipeptide sequence (as IM862) in cancer were small, uncontrolled or negative. Independent replication of a benefit is lacking as of mid-2026.
EU legal status
Not approved as a medicine anywhere in the EU. Available from a small number of specialist research vendors for laboratory immunology research only.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and falls as potency is lost. Above the dashed 80% line the material is considered reliable — hover for exact values.
⚠ A structural estimate, derived from each compound's sequence length, cyclisation and oxidation-, deamidation- and light-sensitive residues. Indicative only — not lab-measured per batch.
Thymagen is not yet in our price comparison
We expand EU supplier coverage every month.
References
- Rat study of the dipeptide (called Thymogen by the group) on aging and spontaneous tumours: longer maximum lifespan and fewer tumours were reported. Animal data from one group only. Anisimov VN, Khavinson VK, Morozov VG. Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats. Biogerontology. 2000;1:55-59. DOIPubMed 11707921
- Randomised phase 2 trial of intranasal IM862 (L-Glu-L-Trp) in AIDS-related Kaposi's sarcoma with 44 patients. It reports 36% major responses and mild side effects, but compared two schedules without a placebo arm. Tulpule A, Scadden DT, Espina BM, Cabriales S, Howard W, Shea K, Gill PS. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol. 2000;18(4):716-723. DOIPubMed 10673512
- Phase 2 trial of IM862 in 25 patients with metastatic renal cell carcinoma: no objective responses, 8 with stable disease. It shows no anticancer efficacy in that setting. Deplanque G, Madhusudan S, Jones PH, Wellmann S, Christodoulos K, Talbot DC, Ganesan TS, Blann A, Harris AL. Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma. Br J Cancer. 2004;91(9):1645-1650. DOIPubMed 15354209
- Phase 3 trial in AIDS-related Kaposi's sarcoma; the title reports IM862 as ineffective, with the effect seen attributed to antiretroviral therapy. Only the title and DOI were verified here (the page itself could not be opened), so no numbers are quoted. AIDS Malignancy Consortium and IM862 Study Team. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a Phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy. J Clin Oncol. DOI
- Review by the originating group listing Thymogen (Glu-Trp) among the synthetic peptides that slowed aging and tumour development in rodents, and mentioning long-term clinical use. Details of the human data were not accessible in the parts read. Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. DOI